The American Medical Association develops new Category III CPT® Codes for implantation of sub-scalp, continuous EEG monitoring system
Major milestone in process of establishing Minder reimbursement in the United States
Melbourne, Australia – October 23, 2024 – Epi-Minder Pty Ltd, a medical technology company focused on the development and commercialization of a sub-scalp Continuous Electroencephalogram (EEG) Monitoring device, Minder®, announced a significant milestone in bringing this technology to epilepsy patients in the United States. The American Medical Association has created new Category III CPT Codes to report implantation of the sub-scalp Continuous EEG Monitoring system. It is expected that the codes will be available for reporting by health care professionals in July of 2025.
Rohan Hoare, Chief Executive Officer of Epiminder, stated: “The organization has been focused on delivering key milestones to support the introduction of Minder in the US market. We are pleased the AMA recognized the need for new Category III CPT codes to report the implantation of this breakthrough technology. This represents the first step in establishing reimbursement for the Minder device which is designed to deliver a continuous stream of EEG data to assist healthcare professionals with the diagnosis and management of patients with epilepsy.”
About epilepsy
Epilepsy affects 80 million people globally with current medications only effective in two in three cases. More than 250,000 Australians and 3.4 million Americans are currently living with epilepsy, the most common brain disorder worldwide that can affect people at any age. Refractory epilepsy affects 30-40% of these patients, who cannot be adequately managed by drug therapy to remain seizure free.
About Minder
Minder is a minimally invasive device for continuous monitoring of electrographic activity of the brain, providing patients and their doctors with detailed data on brain activity over an extended period. Patients can wear the device as they go about their normal daily activities.
Minder’s long-term monitoring of patients outside of a controlled clinical environment is expected to lead to more effective treatment of underlying conditions, including determining the effectiveness of drug therapies and other potential interventions. Currently the device is for investigational use only.
About Epiminder
Epiminder is a medical device company focused on the development of sub-scalp, Continuous EEG Monitoring system for people who suffer from epilepsy and other seizure disorders where continuous monitoring is required. Epiminder is headquartered in Melbourne, Australia and has subsidiaries operating in the United States.